Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,243 shares of the biopharmaceutical company’s stock after purchasing an additional 262 shares during the quarter. Lecap Asset Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $885,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Atomi Financial Group Inc. increased its holdings in Regeneron Pharmaceuticals by 4.9% in the third quarter. Atomi Financial Group Inc. now owns 575 shares of the biopharmaceutical company’s stock valued at $605,000 after buying an additional 27 shares in the last quarter. Daymark Wealth Partners LLC increased its stake in Regeneron Pharmaceuticals by 20.3% in the 3rd quarter. Daymark Wealth Partners LLC now owns 355 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 60 shares in the last quarter. CWM LLC raised its holdings in Regeneron Pharmaceuticals by 1.1% during the third quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 25 shares during the last quarter. Wedmont Private Capital boosted its position in Regeneron Pharmaceuticals by 4.5% during the third quarter. Wedmont Private Capital now owns 1,496 shares of the biopharmaceutical company’s stock worth $1,490,000 after purchasing an additional 65 shares in the last quarter. Finally, UMB Bank n.a. grew its holdings in Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 10 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. TD Cowen cut their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday. Bank of America restated an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Sanford C. Bernstein lowered their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Trading Down 1.7 %

REGN stock opened at $710.00 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a market cap of $78.02 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $716.62 and a 200-day simple moving average of $913.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $11.86 earnings per share. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.